Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market

$ PRICE - $ 2,000.00$ 6,000.00

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market: Trial Phase ( Preclinical Trials, Phase 1, Phase 2, Phase 3, Phase 4), Drugs (Blinatumomab, Carfilzomib, calaspargasepegol, Dasatinib, Ibrutinib, Inotuzumabozogamicin, Ofatumumab, Ponatinib, Others), Route of Administration (Oral, Parenteral)

 

$ PRICE - $ 2,000.00$ 6,000.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,000.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as Acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc. ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others.

Key Developments:

In March 2015, Novartis Pharmaceuticals commenced Phase IIIb Multicenter, open-label, single arm study to evaluate the efficacy and safety of Pasireotide in Patients with acromegaly inadequately controlled with first generation somatostatin analogues.

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market

MARKET SUMMARY
-
x%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– x%
  • Largest Market– Asia Pacific
  • Fastest Growing Market–  North America

Acute Lymphoblastic Leukemia Disease Pipeline Drug

  • The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others.
  • Moreover, the report on Acute Lymphoblastic Leukemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Players
  • Novartis
  • Pfizer
  • Janssen
  • Amgen
  • (Erytech Pharma

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Lymphoblastic Leukemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Lymphoblastic Leukemia disease pipeline drugs development. This report studies the dynamics of the Acute Lymphoblastic Leukemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development.


Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive Summary

2. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Introduction

2.1. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Taxonomy

2.2. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market –Definitions

2.2.1. Trial Phase

2.2.2. Drugs

2.2.3. Route of Administration

3. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis

3.6. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Competition Landscape

3.7. Epidemiology

4. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market opportunity analysis

5. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market, By Trail Phase, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1. Preclinical Trials

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Phase 1

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Phase 2

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

5.4. Phase 3

5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.4.3. Market Opportunity Analysis

5.5. Phase 4

5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.5.3. Market Opportunity Analysis

6. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Forecast, By Drugs,2013 – 2017 and Forecast, 2017 – 2024

6.1. Blinatumomab

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Carfilzomib

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Calaspargasepegol

6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Dasatinib

6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

6.5. Ibrutinib

6.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.5.3. Market Opportunity Analysis

6.6. Inotuzumabozogamicin

6.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.6.3. Market Opportunity Analysis

6.7. Ofatumumab

6.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.7.3. Market Opportunity Analysis

6.8. Ponatinib

6.8.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.8.3. Market Opportunity Analysis

6.9. Others

6.9.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.9.3. Market Opportunity Analysis

7. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1. Oral

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Parenteral

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

8. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1. North America

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

9. North America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

9.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Preclinical Trials

9.1.2. Phase 1

9.1.3. Phase 2

9.1.4. Phase 3

9.1.5. Phase 4

9.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Blinatumomab

9.2.2. Carfilzomib

9.2.3. calaspargasepegol

9.2.4. Dasatinib

9.2.5. Ibrutinib

9.2.6. Inotuzumabozogamicin

9.2.7. Ofatumumab

9.2.8. Ponatinib

9.2.9. Others

9.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Oral

9.3.2. Parenteral

9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

9.6. North America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

10. Europe Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

10.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Preclinical Trials

10.1.2. Phase 1

10.1.3. Phase 2

10.1.4. Phase 3

10.1.5. Phase 4

10.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Blinatumomab

10.2.2. Carfilzomib

10.2.3. calaspargasepegol

10.2.4. Dasatinib

10.2.5. Ibrutinib

10.2.6. Inotuzumabozogamicin

10.2.7. Ofatumumab

10.2.8. Ponatinib

10.2.9. Others

10.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Oral

10.3.2. Parenteral

10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

10.6. Europe Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

11. Asia-Pacific Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

11.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Preclinical Trials

11.1.2. Phase 1

11.1.3. Phase 2

11.1.4. Phase 3

11.1.5. Phase 4

11.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Blinatumomab

11.2.2. Carfilzomib

11.2.3. calaspargasepegol

11.2.4. Dasatinib

11.2.5. Ibrutinib

11.2.6. Inotuzumabozogamicin

11.2.7. Ofatumumab

11.2.8. Ponatinib

11.2.9. Others

11.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Oral

11.3.2. Parenteral

11.4. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

11.6. Asia-Pacific Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

12. Latin America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

12.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Preclinical Trials

12.1.2. Phase 1

12.1.3. Phase 2

12.1.4. Phase 3

12.1.5. Phase 4

12.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Blinatumomab

12.2.2. Carfilzomib

12.2.3. calaspargasepegol

12.2.4. Dasatinib

12.2.5. Ibrutinib

12.2.6. Inotuzumabozogamicin

12.2.7. Ofatumumab

12.2.8. Ponatinib

12.2.9. Others

12.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Oral

12.3.2. Parenteral

12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

12.6. Latin America Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

13. Middle East and Africa Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

13.1. Trail Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

13.1.1. Preclinical Trials

13.1.2. Phase 1

13.1.3. Phase 2

13.1.4. Phase 3

13.1.5. Phase 4

13.2. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Blinatumomab

13.2.2. Carfilzomib

13.2.3. calaspargasepegol

13.2.4. Dasatinib

13.2.5. Ibrutinib

13.2.6. Inotuzumabozogamicin

13.2.7. Ofatumumab

13.2.8. Ponatinib

13.2.9. Others

13.3. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.3.1. Oral

13.3.2. Parenteral

13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. Gulf Cooperation Council (GCC) Countries

13.4.2. Israel

13.4.3. South Africa

13.4.4. Rest of MEA

13.5. MEA Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Trial Phase, By Drugs, By Route of Administration and Region, 2018 – 2024

13.6. MEA Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment Market Dynamics – Trends

14. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Novartis

14.2.2. Pfizer

14.2.3. Ariad Pharmaceuticals

14.2.4. Juno Therapeutics

14.2.5. Janssen

14.2.6. Amgen

14.2.7. (Erytech Pharma

14.2.8. Bristol-Myers Squibb

14.2.9. Others

15. Research Methodology

16. Key Assumptions and Acronyms


Report

Company Profile

  • Novartis
  • Pfizer
  • Ariad Pharmaceuticals
  • Juno Therapeutics
  • Janssen
  • Amgen
  • (Erytech Pharma
  • Bristol-Myers Squibb

Description

Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as Acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc. ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others.

Key Developments:

In March 2015, Novartis Pharmaceuticals commenced Phase IIIb Multicenter, open-label, single arm study to evaluate the efficacy and safety of Pasireotide in Patients with acromegaly inadequately controlled with first generation somatostatin analogues.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX